Analysts' Actions: Alibaba, Oracle, Sprouts, Texas Capital, More

NEW YORK (TheStreet) -- RATINGS CHANGES

Alibaba (BABA) was initiated with a buy rating at Cantor Fitzgerald. Twelve-month price target is $90. Company has an unfair competitive advantage with outsized growth and margin profiles, Cantor said.

Bio-Rad Laboratories (BIO) was downgraded to hold at TheStreet Ratings. You can view the full analysis from the report here: BIO Ratings Report.

Oracle (ORCL) was downgraded at Deutsche Bank to hold from buy. Twelve-month price target is $42. Database license sales are slowing down, Deutsche Bank said.

Koss (KOSS) was downgraded to sell at TheStreet Ratings. You can view the full analysis from the report here: KOSS Ratings Report.

Sprouts (SFM) was initiated with an overweight rating at Barclays. Twelve-month price target is $37. Company can average 33% earnings growth over the next five years, Barclays said.

Texas Capital (TCBI) was upgraded at Wunderlich to buy from hold. Twelve-month price target is $75. Company is the most sensitive to higher interest rates, Wunderlich said.

VF (VFC) was upgraded at Keybanc to buy. Twelve-month price target is $80. Estimates were also increased, as the company will likely improve brands and could make acquisitions, Keybanc said.

Editor's note: To see analysts' stock comments and changes to price targets and earnings estimates, go to "Street Notes" which is available only to Real Money subscribers. To find out how to become a subscriber, please click here.

Follow TheStreet on Twitter and become a fan on Facebook.

This article was written by a staff member of TheStreet.

More from Stocks

Dow Finishes Lower as Nasdaq Posts New Record

Dow Finishes Lower as Nasdaq Posts New Record

News From Starbucks and General Electric Leaves Their Investors Up in Arms

News From Starbucks and General Electric Leaves Their Investors Up in Arms

3 Ways to Fix Starbucks Biggest Challenges

3 Ways to Fix Starbucks Biggest Challenges

Sarepta Shares Keep Climbing and PTC Therapeutics Bounces Back

Sarepta Shares Keep Climbing and PTC Therapeutics Bounces Back

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists